Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Depomed
ClinicalTrials.gov Identifier:
NCT01515410
First received: January 11, 2012
Last updated: January 27, 2014
Last verified: November 2012

January 11, 2012
January 27, 2014
January 2012
September 2012   (final data collection date for primary outcome measure)
The Primary Objective of This Study is to Explore the Efficacy and Tolerability of DM-1992 Compared to a Standard CD/LD IR Formulation as Measured by Percent "OFF" Time. [ Time Frame: Baseline and 10 days for each of the 2 study periods ] [ Designated as safety issue: Yes ]

"OFF" indicates wearing off motor fluctuations before the next levodopa dose. Percent "OFF" time is calculated as the total "OFF" time divided by the total awake time for each day and multiplied by 100.

Patient diary-every 30min while awake for 3days prior to initial Day1 as baseline & during the last 3days before Day10 for both treatments for dyskinesia state.

Baseline is the average of the 3 days recorded in the patient diary prior to Day 1 of Period 1.

End of Period is the average of the 3 days recorded in the patient diary prior to Day 10 in each period.

Clinician-Assess efficacy at pre-dose, every 30min for Day1 and hourly for Day10 for dyskinesia state & motor fluctuations at clinic visits.

The Primary objective of this study is to explore the efficacy and tolerability of DM-1992 compared to a standard CD/LD IR formulation as measured by patients "ON" time with no dyskinesia or non-troublesome dyskinesia and "OFF" time [ Time Frame: 10 days treatment ] [ Designated as safety issue: Yes ]

Ptdiary-every 30min while awake for 3days prior to initial Day1 as baseline & during the last 3days before Day10 for both treatments for dyskinesia state.

Clinician-Assess efficacy at pre-dose,every 30min for Day1 and hourly for Day10 for dyskinesia state & motor fluctuations at clinic visits.

Complete list of historical versions of study NCT01515410 on ClinicalTrials.gov Archive Site
Not Provided
Secondary objective is pharmacokinetics measures [ Time Frame: 24hours ] [ Designated as safety issue: No ]

Pharmacokinetic parameters will be-

  • AUC0-t
  • Cmax
  • Cmin
  • tmax
  • Fluctuation index defined as the ratio of Cmax/Cmin
  • Deviation from the average LD concentration
  • Relation between the efficacy and duration of concentration above certain level(eg.300ng/mL & 1000ng/mL)will be explored.
Not Provided
Not Provided
 
Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations
A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations

The primary objective of this study is to explore the efficacy and tolerability of DM-1992 compared to a standard carbidopa/Levodopa Immediate-Release (CD/LD IR) tablet (Sinemet IR) as measured by:

  • "ON" time with no dyskinesia or non-troublesome dyskinesia
  • "OFF" time
Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Parkinson's Disease
  • Motor Fluctuations
  • Drug: DM-1992
    72.5mg carbidopa/230mg levodopa
  • Drug: Sinemet IR
    Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
  • Experimental: DM-1992
    DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
    Intervention: Drug: DM-1992
  • Active Comparator: Sinemet IR
    An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
    Intervention: Drug: Sinemet IR
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
34
October 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Men and women at least 30 years and older at the time of informed consent with advanced idiopathic Parkinson's disease with predictable wearing-off motor fluctuations with Hoehn and Yahr Stage II-III when "on."
  2. Patients should be able to differentiate between the "ON" and "OFF" states with an average daily "OFF" time of ≥ 2.5 hours at study entry.
  3. On a stable daily dose of LD of ≥ 400 mg but ≤1600 mg for at least 1 month prior to the screening visit.
  4. Non CD/LD containing anti-Parkinson's medications should be kept at stable doses for 1 month prior to screening visit. Patients should be willing to keep their non LD containing medications consistently throughout the study duration.
  5. Female patients of childbearing potential should be abstinent or continuing to practice and willing to continue throughout the study with appropriate contraceptives (defined as Nova ring, oral, injected, transdermal patch, implanted, or barrier).
  6. Mini Mental State Examination (MMSE) ≥ 26 at screening visit.
  7. Able to provide informed consent and willing to sign Health Insurance Portability and Accountability Act (HIPAA) authorization.
  8. Able and willing to comply with the protocol, including availability for all scheduled study visits and blood sample collections. Must be under the observation of a competent care giver throughout the study participation.

Exclusion Criteria:

  1. Patients with atypical or drug-induced Parkinson's disease.
  2. Patients with a known history of hypersensitivity to levodopa or carbidopa.
  3. Patients who receive treatments with dopamine receptor blocking agents
  4. Patients with a history of seizures except of childhood febrile seizure.
  5. Patients with dementia.
  6. Patients with a significant history of GI diseases (severe inflammatory bowel disease, irritable bowel disease, dyspepsia, gastro-esophageal reflux disease etc.) in the past five years.
  7. Patients with any history of gastric surgery other than vagotomy and pyloroplasty.
  8. Patients with an immune-compromised state.
  9. Patients with clinically significant hepatic insufficiency with Child-Pugh total score of ≥ 5.
  10. Patients with a calculated creatinine clearance (Clcr) < 50 mL/min using the Cockcroft-Gault equation.
  11. Patients who have a difficulty swallowing tablets.
  12. Patient has participated in a clinical trial of an investigational drug or device within 30 days of the screening visit.
  13. Patients with any other serious medical condition that, in the opinion of the Investigator would jeopardize the safety of the patient or affect the validity of the study results.
Both
30 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01515410
81-0068
No
Depomed
Depomed
Not Provided
Study Director: Rekha Sathyanarayana Depomed
Depomed
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP